Compare RUN & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUN | IDYA |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | 2015 | 2019 |
| Metric | RUN | IDYA |
|---|---|---|
| Price | $12.47 | $31.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 16 |
| Target Price | $18.80 | ★ $52.86 |
| AVG Volume (30 Days) | ★ 7.6M | 1.5M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.35 | 61.90 |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $858,578,000.00 | $218,710,000.00 |
| Revenue This Year | $2.81 | N/A |
| Revenue Next Year | $4.54 | $201.05 |
| P/E Ratio | $6.87 | ★ N/A |
| Revenue Growth | 12.97 | ★ 3024.43 |
| 52 Week Low | $5.38 | $16.82 |
| 52 Week High | $22.44 | $39.28 |
| Indicator | RUN | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 46.80 |
| Support Level | $12.01 | $29.51 |
| Resistance Level | $13.57 | $34.76 |
| Average True Range (ATR) | 0.69 | 2.02 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 24.75 | 18.94 |
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.